Levetiracetam Al

Levetiracetam, the active ingredient in Levetiracetam Al, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial seizures, generalized tonic‑clonic seizures, and myoclonic seizures in patients diagnosed with epilepsy.

GNH USA supplies Levetiracetam Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels that meet EU regulatory standards. The company ensures product integrity through rigorous quality control and provides logistical support for global procurement.

Levetiracetam is an antiepileptic medication used to control seizure activity across several seizure types.

- Partial seizures: reduces frequency and severity of focal onset seizures. - Generalized tonic-clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy. - Myoclonic seizures: decreases sudden muscle jerks associated with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate cranial pain. - Irritability: mood changes or agitation. - Nausea: gastrointestinal discomfort. - Fatigue: reduced energy levels.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, hives, or difficulty breathing. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Suicidal thoughts: emergence of depressive ideation or self‑harm urges. - Severe depression: marked mood decline requiring urgent evaluation. - Blood disorders: thrombocytopenia or leukopenia. - Rash: widespread or persistent cutaneous eruption.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure patient safety.

- Renal impairment: dose may need adjustment in patients with reduced kidney function. - Hepatic dysfunction: monitor liver enzymes during therapy. - Psychiatric symptoms: watch for mood changes, irritability, or depression. - Pregnancy: safety not established; use only if benefit outweighs risk. - Concomitant CNS depressants: may enhance sedation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Enzyme‑inducing antiepileptics (phenytoin, phenobarbital): may decrease efficacy. - Strong CYP3A4 inhibitors (ketoconazole): may increase levetiracetam concentrations.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs): possible increased irritability. - Alcohol: additive central nervous system depression. - Oral contraceptives: may slightly reduce hormonal efficacy.